Filing Flows › Fortress Biotech (FBIO) › Q4 2024
Fortress Biotech (FBIO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Fortress Biotech (FBIO) reported revenue of $15.1M for the fourth quarter 2024 (Q4 2024), -24% from a year earlier and +3% from the quarter before. Operating margin was -157.6%, net loss $26.3M (174.0% of revenue).
Fortress Biotech, Q4 2024: revenue $15.1M (-24% year over year), operating margin -157.6%, net loss $26.3M, operating cash flow −$12.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.1M | +3% | -24% |
| Operating profit | −$23.8M | — | — |
| Net earnings | −$26.3M | — | — |
| Operating cash flow | −$12.9M | — | — |
What changed
Revenue was $15.1M in Q4 2024, down 24% year over year and up 3% from the previous quarter. Qbrexza was the largest line at 38% of revenue.
Operating costs exceeded revenue by $23.8M, an operating margin of -157.6%. Total costs fell 2% while revenue fell 24%. The fastest-growing cost line was SG&A (+38%). The quarter ended with a net loss of $26.3M, narrower than the previous quarter's $26.7M loss. Minority interests bore $19.6M of it: to shareholders the quarter was a loss of $6.8M.
Operating cash flow was −$12.9M. Non-cash charges added back $1.1M of depreciation and amortization and $16.2M of share-based compensation. Working capital and other items used $3.9M.
Questions
What was Fortress Biotech's revenue in the fourth quarter 2024?
Fortress Biotech (FBIO) reported revenue of $15.1M for the fourth quarter 2024 (Q4 2024), -24% from a year earlier and +3% from the quarter before.
Was Fortress Biotech profitable in the fourth quarter 2024?
Operating loss was $23.8M (-157.6% of revenue) and net loss $26.3M.
Source: Fortress Biotech 10-K on SEC EDGAR.